Close Menu

NEW YORK – C2i Genomics said on Tuesday that it has raised $12 million in a Series A financing round, led by Casdin Capital and joined by additional new investors including NFX Capital, The Mark Foundation for Cancer Research, and others.

The New York-based startup will use the funding to develop and clinically validate its personalized, real-time tool for monitoring recurrence and treatment response for various types of solid cancers.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.